A. U. Berestovskaia
Research Subjects
A. U. Berestovskaia has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Erovichenkov
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences; Russian Medical Academy of Postgraduate Education
3 shared publications - Denis Nikolaevich Protsenko
Pirogov Russian National Research Medical University
3 shared publications - E. A. Artamonova
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)
3 shared publications - Olga N. Solodovnikova
Moscow Multidisciplinary Clinical Center «Kommunarka
3 shared publications - S. K. Pylaeva
N.I. Pirogov Russian National Research Medical University Ministry of Health of Russia; M.P. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences
3 shared publications - A. Yu. Dyagileva
Moscow Multidisciplinary Clinical Center «Kommunarka» of the Moscow Department of Health
2 shared publications
Latest Publications
- Open Access
- 6 November 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (5) , 63-72
Neutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
SARS-CoV-2 has been actively circulating in the human population since late 2019. During this time, the virus acquired more than 140 nucleotide mutations and 20 deletions per genome from the original variant identified in Wuhan. As the virus circulates, the proportion of re-infected individuals increases, but it is unclear how well neutralizing antibodies formed by infection with early variants neutralize the new Omicron variant lines. We analyzed the neutralizing activity of 286 sera from 286 adult patients with COVID-19 in 2020-2021, during the circulation of the prototypical lines and the Delta variant of SARS-CoV-2, against strains of the original lines and the Omicron ВА.1 and ХВВ.1.9. 2. About 10% of the sera of people who overexperienced COVID-19 while the prototypical strains were circulating and about 50% of people who overexperienced it while the Delta variant was circulating contain antibodies that neutralize Omicron ХВВ.1.9 was circulating in 2023. Thus, a fraction of people, regardless of age, who became infected in 2020-2021 have an antibody spectrum capable of neutralizing current and possibly related SARS-CoV-2 variants that will emerge in the near future. However, no strong positive correlation was found between IgG levels to RBD and NAТ titers to SARS-CoV-2 (R < 0.5), which may complicate serologic diagnosis of COVID-19 and lead to inappropriate assessment of human protection and the presence of an immune layer to SARS-CoV-2 in population-based studies.
- 6 November 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (5) , 63-72
Open AccessNeutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
SARS-CoV-2 has been actively circulating in the human population since late 2019. During this time, the virus acquired more than 140 nucleotide mutations and 20 deletions per genome from the original variant identified in Wuhan. As the virus circulates, the proportion of re-infected individuals increases, but it is unclear how well neutralizing antibodies formed by infection with early variants neutralize the new Omicron variant lines. We analyzed the neutralizing activity of 286 sera from 286 adult patients with COVID-19 in 2020-2021, during the circulation of the prototypical lines and the Delta variant of SARS-CoV-2, against strains of the original lines and the Omicron ВА.1 and ХВВ.1.9. 2. About 10% of the sera of people who overexperienced COVID-19 while the prototypical strains were circulating and about 50% of people who overexperienced it while the Delta variant was circulating contain antibodies that neutralize Omicron ХВВ.1.9 was circulating in 2023. Thus, a fraction of people, regardless of age, who became infected in 2020-2021 have an antibody spectrum capable of neutralizing current and possibly related SARS-CoV-2 variants that will emerge in the near future. However, no strong positive correlation was found between IgG levels to RBD and NAТ titers to SARS-CoV-2 (R < 0.5), which may complicate serologic diagnosis of COVID-19 and lead to inappropriate assessment of human protection and the presence of an immune layer to SARS-CoV-2 in population-based studies.
- Open Access
- 24 September 2024
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 23 (3) , 19-25
Clinical and epidemiological characteristics of imported intestinal infections in children
Клинико-эпидемиологическая характеристика завозных кишечных инфекций у детей
- 24 September 2024
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 23 (3) , 19-25
Open AccessClinical and epidemiological characteristics of imported intestinal infections in children
Клинико-эпидемиологическая характеристика завозных кишечных инфекций у детей
- Open Access
- 27 June 2023
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 22 (2) , 12-17
Early warning system of clinical deterioration in pediatric patients with common cold
Раннее выявление риска клинического ухудшения у пациентов детского возраста при острых респираторных вирусных инфекциях
- 27 June 2023
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 22 (2) , 12-17
Open AccessEarly warning system of clinical deterioration in pediatric patients with common cold
Раннее выявление риска клинического ухудшения у пациентов детского возраста при острых респираторных вирусных инфекциях